Literature DB >> 32044865

Vaginal Microbiota and Mucosal Immune Markers in Women With Vulvovaginal Discomfort.

Caroline M Mitchell1, LaTina Watson1, Alissa J Mitchell1, Ollivier Hyrien2, Agnes Bergerat1, D J Valint2, Alisa Pascale1, Noah Hoffman3, Sujatha Srinivasan2, David N Fredricks2.   

Abstract

BACKGROUND: Up to 30% of women with vaginal symptoms are not assigned a diagnosis after standard diagnostic assessment.
METHODS: We compared premenopausal women with idiopathic vaginitis (IV) or vulvodynia (VVD) to healthy controls. Microbiota were characterized using rRNA sequencing. Cytokines/chemokines (IL-10, IL-1α, IL-1β, IL-6, IL-8, IL-2, IL-18, IL-4, IL-9, and IL-13) were measured in vaginal lavage fluid using the Meso Scale Discovery platform or ELISA (IL-1ra). Immunoglobulins were measured in vaginal lavage fluid using a bead-based immunoassay (Millipore). Cases and controls were compared using Kruskal-Wallis, analysis of variance, and linear regression or (for microbiome composition) the Bray-Curtis dissimilarity statistic.
RESULTS: We compared 20 women with IV, 30 with VVD, and 52 controls. Most (80%) had greater than 90% 16S rRNA gene sequences from Lactobacillus crispatus, L. jensenii, L. gasseri, or L. iners. In analyses adjusted for age and hormonal contraception (HC), Gardnerella vaginalis was less prevalent and abundant in women with VVD (2/30, 7%) versus controls (16/52, 31%) or IV (5/20, 25%) (P = 0.030). Bray-Curtis dissimilarity was not significantly different between IV and controls or VVD. Fungal sequences were only detected in 5 participants: 2 control, 1 IV, 2 VVD. In univariate analysis, cytokines were not associated with diagnosis. Median vaginal concentration of IgE (but not other immunoglobulins) was lower in women with VVD (P = 0.006).
CONCLUSIONS: Minimal differences in vaginal microbiota and inflammatory markers between women with IV, VVD or controls suggest no striking association between vaginal bacteria, fungi or inflammation and diagnosis in these women.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32044865      PMCID: PMC7071966          DOI: 10.1097/OLQ.0000000000001143

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   3.868


  30 in total

1.  Enhanced synthesis of proinflammatory cytokines by vulvar vestibular fibroblasts: implications for vulvar vestibulitis.

Authors:  David C Foster; Katherine H Piekarz; Thomas I Murant; Randi LaPoint; Constantine G Haidaris; Richard P Phipps
Journal:  Am J Obstet Gynecol       Date:  2007-04       Impact factor: 8.661

2.  Impact of vaginal antifungal products on utilization of health care services: evidence from physician visits.

Authors:  M S Lipsky; T Waters; L K Sharp
Journal:  J Am Board Fam Pract       Date:  2000 May-Jun

3.  Vulvovaginal Discomfort Is Common in Both Premenopausal and Postmenopausal Women.

Authors:  LaTina J Watson; Kaitlyn E James; Ida J Hatoum Moeller; Caroline M Mitchell
Journal:  J Low Genit Tract Dis       Date:  2019-04       Impact factor: 1.925

4.  Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation.

Authors:  R P Nugent; M A Krohn; S L Hillier
Journal:  J Clin Microbiol       Date:  1991-02       Impact factor: 5.948

5.  Hypersensitivity to aeroallergens in patients with recurrent vulvovaginitis of undetermined etiology.

Authors:  Sami Ozturk; Zafer Caliskaner; Mehmet Karaayvaz; Murat Dede; Mustafa Gulec
Journal:  J Obstet Gynaecol Res       Date:  2007-08       Impact factor: 1.730

Review 6.  Evaluation of vaginal complaints.

Authors:  Matthew R Anderson; Kathleen Klink; Andreas Cohrssen
Journal:  JAMA       Date:  2004-03-17       Impact factor: 56.272

7.  Abnormal vaginal microbioma is associated with severity of localized provoked vulvodynia. Role of aerobic vaginitis and Candida in the pathogenesis of vulvodynia.

Authors:  Gilbert G G Donders; Gert Bellen; Kateryna S Ruban
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-22       Impact factor: 3.267

8.  Is Cryotherapy Friend or Foe for Symptomatic Cervical Ectopy?

Authors:  Yasemin Çekmez; Fatih Şanlıkan; Ahmet Göçmen; Aylin Vural; Simge Bağcı Türkmen
Journal:  Med Princ Pract       Date:  2015-10-27       Impact factor: 1.927

9.  Clinical Validation of the Aptima Bacterial Vaginosis and Aptima Candida/Trichomonas Vaginitis Assays: Results from a Prospective Multicenter Clinical Study.

Authors:  Jane R Schwebke; Stephanie N Taylor; Ronald Ackerman; Robert Schlaberg; Neil B Quigley; Charlotte A Gaydos; Steven E Chavoustie; Paul Nyirjesy; Carmelle V Remillard; Philip Estes; Byron McKinney; Damon K Getman; Craig Clark
Journal:  J Clin Microbiol       Date:  2020-01-28       Impact factor: 5.948

10.  Neuroepithelial control of mucosal inflammation in acute cystitis.

Authors:  Daniel S C Butler; Ines Ambite; Karoly Nagy; Caterina Cafaro; Abdulla Ahmed; Aftab Nadeem; Nina Filenko; Thi Hien Tran; Karl-Erik Andersson; Björn Wullt; Manoj Puthia; Catharina Svanborg
Journal:  Sci Rep       Date:  2018-07-20       Impact factor: 4.379

View more
  6 in total

1.  Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation.

Authors:  Seth M Bloom; Nomfuneko A Mafunda; Benjamin M Woolston; Matthew R Hayward; Josephine F Frempong; Aaron B Abai; Jiawu Xu; Alissa J Mitchell; Xavier Westergaard; Fatima A Hussain; Nondumiso Xulu; Mary Dong; Krista L Dong; Thandeka Gumbi; F Xolisile Ceasar; Justin K Rice; Namit Choksi; Nasreen Ismail; Thumbi Ndung'u; Musie S Ghebremichael; David A Relman; Emily P Balskus; Caroline M Mitchell; Douglas S Kwon
Journal:  Nat Microbiol       Date:  2022-03-03       Impact factor: 30.964

2.  Association between postmenopausal vulvovaginal discomfort, vaginal microbiota, and mucosal inflammation.

Authors:  Caroline M Mitchell; Nanxun Ma; Alissa J Mitchell; Michael C Wu; D J Valint; Sean Proll; Susan D Reed; Katherine A Guthrie; Andrea Z Lacroix; Joseph C Larson; Robert Pepin; Daniel Raftery; David N Fredricks; Sujatha Srinivasan
Journal:  Am J Obstet Gynecol       Date:  2021-03-04       Impact factor: 10.693

3.  The Vaginal Microbiome: III. The Vaginal Microbiome in Various Urogenital Disorders.

Authors:  Francesco De Seta; Risa Lonnee-Hoffmann; Giuseppina Campisciano; Manola Comar; Hans Verstraelen; Pedro Vieira-Baptista; Gary Ventolini; Ahinoam Lev-Sagie
Journal:  J Low Genit Tract Dis       Date:  2022-01-01       Impact factor: 1.925

4.  molBV reveals immune landscape of bacterial vaginosis and predicts human papillomavirus infection natural history.

Authors:  Mykhaylo Usyk; Nicolas F Schlecht; Sarah Pickering; LaShanda Williams; Christopher C Sollecito; Ana Gradissimo; Carolina Porras; Mahboobeh Safaeian; Ligia Pinto; Rolando Herrero; Howard D Strickler; Shankar Viswanathan; Anne Nucci-Sack; Angela Diaz; Robert D Burk
Journal:  Nat Commun       Date:  2022-01-11       Impact factor: 14.919

5.  Bacterial Communities Associated With Abnormal Nugent Score in Postmenopausal Versus Premenopausal Women.

Authors:  Caroline M Mitchell; Sujatha Srinivasan; Nanxun Ma; Susan D Reed; Michael C Wu; Noah G Hoffman; Daniel J Valint; Sean Proll; Tina L Fiedler; Kathy J Agnew; Katherine A Guthrie; David N Fredricks
Journal:  J Infect Dis       Date:  2021-06-15       Impact factor: 5.226

6.  Vulvodynia associated with vulvovaginal microbiome: Neglected due to the COVID-19 pandemic?

Authors:  S Rozani; K Evangelou; C Tsagkaris
Journal:  Ethics Med Public Health       Date:  2021-12-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.